Alkermes (ALKS) Operating Income (2010 - 2026)
Alkermes' (ALKS) quarterly Operating Income came in at $18.4 million in Q2 2026, down 80.26% year-over-year from $93.0 million in Q2 2025, and up 138.01% quarter-over-quarter from -$48.3 million in Q1 2026.
Analysis
Alkermes (ALKS) Operating Income (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Operating Income for 17 consecutive years, with $18.4 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Operating Income fell 80.26% year-over-year to $18.4 million in Q2 2026; TTM through Jun 2026 was $117.3 million, a 68.67% decrease from a year earlier, with the FY2025 full-year figure at $254.0 million, down 39.63% from the prior year.
- Operating Income was $18.4 million for Q2 2026 at Alkermes, up from -$48.3 million in the prior quarter.
- Over five years, Operating Income peaked at $281.3 million in Q2 2023 and troughed at -$60.6 million in Q3 2022.
- A 5-year average of $58.5 million and a median of $56.4 million in 2023 frame the typical range for Operating Income.
- Across the five-year window, Operating Income slumped 879.39% in 2022 and surged 916.29% in 2023, its largest moves.
- Over 5 years, Operating Income stood at $115.6 million in 2022, then slumped by 52.74% to $54.6 million in 2023, then surged by 197.79% to $162.7 million in 2024, then slumped by 64.29% to $58.1 million in 2025, then slumped by 68.41% to $18.4 million in 2026.
- The last three Operating Income figures came in at $18.4 million (Q2 2026), -$48.3 million (Q1 2026), and $58.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.92 Bn | 626.16 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 441.93 Bn | 435.36 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 365.88 Bn | 358.74 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn | 4.27 Bn |
| 6 | Sanofi | 52.44 Bn | 45.05 Bn | 10.79 Bn | 1.22 Bn |
| 7 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -505.13 Mn |
| 8 | Incyte | 25.31 Bn | 20.78 Bn | 1.57 Bn | 697.90 Mn |
| 9 | United Therapeutics | 21.45 Bn | 18.78 Bn | 683.80 Mn | 330.80 Mn |
| 10 | Alkermes | 7.57 Bn | 6.91 Bn | 397.90 Mn | 18.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.35 Mn |
| Mar 31, 2026 | -48.28 Mn |
| Dec 31, 2025 | 58.10 Mn |
| Sep 30, 2025 | 89.08 Mn |
| Jun 30, 2025 | 92.98 Mn |
| Mar 31, 2025 | 13.79 Mn |
| Dec 31, 2024 | 162.69 Mn |
| Sep 30, 2024 | 104.76 Mn |
| Jun 30, 2024 | 109.88 Mn |
| Mar 31, 2024 | 43.31 Mn |
| Dec 31, 2023 | 54.63 Mn |
| Sep 30, 2023 | 89.19 Mn |
| Jun 30, 2023 | 281.27 Mn |
| Mar 31, 2023 | -10.97 Mn |
| Dec 31, 2022 | 115.59 Mn |
| Sep 30, 2022 | -60.64 Mn |
| Jun 30, 2022 | -34.46 Mn |
| Mar 31, 2022 | -26.59 Mn |
| Dec 31, 2021 | 129.42 Mn |
| Sep 30, 2021 | -19.66 Mn |